engleski

Assessment of atorvastatin genotoxicity on human lymphocytes using sister-chromatid exchange analysis

Recent blood cholesterol level reducing therapy is based on ten different statins that are today found in different generic names. Some of them are still in the phase of controlled clinical trials. Statins, especially atorvastatin are first-line therapy for reducing low-density lipoprotein (LDL) levels in patients at high risk for atherosclerotic cardiovascular disease. In this study we investigated the genotoxic potential of atorvastatin on human lymphocytes using sister-chromatid exchange (SCE) analysis. Lymphocyte cultures were treated with a single drug at a concentration of 30.21 ng/ml. For sister-chromatid exchange (SCE) analysis, cells were grown on medium for 72 h. Each sample was characterized by considering the mean (&plusmn ; standard error of the mean), range of SCE per cell and the proportion of cells with a high frequency of SCE, i.e. HFC. Results of the SCE analysis did show statistically significant differences in the mean SCE number and incidence of HFC between atorvastatin-exposed and control human lymphocytes and between different exposure times. Results obtained in this study point to the significance of biological indicators providing information on the primary genome damage after long-term exposure, which can help to establish drug therapeutic concentrations that do not put patients with high blood cholesterol to a greater treatment-related risk.

sister-chromatid exchange; atorvastatin; human lymphocytes

nije evidentirano